Objectives: To evaluate the long-term efficacy of treating nasal telangiectasias with the TRASER device. Methods: Subjects from the TRASER efficacy analysis clinical trial were invited for a 1-year follow-up. Standardized photographs were taken to compare to baseline. The same clinical trial evaluator graded the subjects’ current vessel clearance using the 5-point telangiectasia scale. The data was compiled and analyzed. Results: Of the subjects with available follow-up data, 44% maintained “complete vessel clearance,” 44% dropped down one grade to “almost complete vessel clearance,” and 11% dropped down to “moderately clear vessel clearance.” All showed clinically significant improvement in nasal telangiectasias from baseline. Conclusions: The TRASER effectively treats nasal telangiectasias with minimal to mild recurrence at 1-year follow-up. Lasers Surg. Med. 50:61–63, 2018.
ASJC Scopus subject areas